News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes -
-
-
COMMUNIQUÉ DE PRESSE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders